InspireMD, a medical device company engaged in the development and commercialisation of the mesh-based MGuard stent systems, reported that mesh-based protection, is now recommended for use in the new guidelines of the task force of myocardial revascularisation of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions." It has received a class IIb recommendation.

Currently, this type of approved mesh technology is exclusively used by InspireMD in its unique and patent pending MGuard mesh protected coronary stent system. "We are satisfied that the InspireMD mission and technology to improve the outcome of PCI in AMI, was acknowledged by the ESC. In the light of the extremely positive experience gathered with MGuard we are much honored that the ESC acknowledges the MGuard mesh technology for thrombotic lesions. The outcome from our clinical studies in Acute MI as well as SVG patients is very positive and we are very encouraged by this recognition of the European Society of Mguard," stated Ofir Paz, CEO, InspireMD.

MGuard presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard which is a CE mark approved coronary stent, provides permanent embolic protection, without affecting deliverability. The MGuard Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

InspireMD is an innovative medical device company focusing on the development and commercialisation of its proprietary stent system technology, MGuard. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilise its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting like restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimising arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.